NASDAQ: TLSATiziana Life Sciences Ltd Stock
$1.17-0.14 (-10.69%)
Updated Jul 6, 2026
TLSA Price
$1.17
Fair Value Price
$0.08
Market Cap
$140.99M
52 Week Low
$1.04
52 Week High
$2.60
P/E
-7.31x
P/B
2,711.42x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.43M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
220.06
Operating Cash Flow
-$13M
Beta
0.66
Next Earnings
Aug 7, 2026
Ex-Dividend
N/A
Next Dividend
N/A
TLSA Overview
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TLSA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important TLSA news, forecast changes, insider trades & much more!
TLSA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TLSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TLSA ($1.17) is overvalued by 1,357.82% relative to our estimate of its Fair Value price of $0.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TLSA ($1.17) is not significantly undervalued (1,357.82%) relative to our estimate of its Fair Value price of $0.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TLSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TLSA due diligence checks available for Premium users.
Valuation
TLSA fair value
Fair Value of TLSA stock based on Discounted Cash Flow (DCF)
Price
$1.17
Fair Value
$0.08
Overvalued by
1,357.82%
TLSA ($1.17) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TLSA ($1.17) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TLSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TLSA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.31x
Industry
18.36x
Market
6.94x
TLSA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2,711.42x
Industry
5.58x
TLSA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TLSA's financial health
Profit margin
Revenue
$0.0
Net Income
-$18.4M
Profit Margin
0%
TLSA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.5M
Liabilities
$11.4M
Debt to equity
220.06
TLSA's short-term liabilities ($11.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLSA's short-term assets ($8.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLSA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TLSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.8M
Investing
$3.0M
Financing
$10.0M
TLSA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TLSA vs Biotech Stocks
Tiziana Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.